New clinical parameters for determining hematologic toxicity proior to radioimmunotherapy

New clinical parameters for determining hematologic toxicity proior to radioimmunotherapy

  • CN 1,450,911 A
  • Filed: 07/31/2000
  • Published: 10/22/2003
  • Est. Priority Date: 08/11/1999
  • Status: Abandoned Application
First Claim
Patent Images

1. , forecast, is comprised to the seriousness of haematics toxicity due to cancer patient'"'"'s administration and prevention or reduce the method for this haematics toxicity by radiolabeled antibody:

  • (a) bone marrow of measuring in the baseline biopsy involves degree;

    With(b) be higher than 5% if described baseline bone marrow involves degree, with the cold consumption antibody administration of effective dose on the therapeutics, be reduced to less than 5% so so that described bone marrow involves degree.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×